Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream Applied Once Daily 3 Days Per Week for the Treatment of Actinic Keratoses in Immunosuppressed Organ Transplant Recipients.

NCT00189267 is registered in ClinicalTrials.gov with MEDA Pharma GmbH & Co. KG as lead sponsor.

NCT NCT00189267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00189267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream Applied Once Daily 3 Days Per Week for the Treatment of Actinic Keratoses in Immunosuppressed Organ Transplant Recipients.
Lead sponsor
MEDA Pharma GmbH & Co. KG
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2002
Completion date
September 30, 2005
Enrollment
45
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

actinic keratosis